Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Commerce Bank

Commerce Bank increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 36.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 937 shares of the medical research company’s stock after purchasing an additional 252 shares during the period. Commerce Bank’s holdings in Bio-Rad Laboratories were worth $699,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Atticus Wealth Management LLC boosted its stake in Bio-Rad Laboratories by 68.3% in the 3rd quarter. Atticus Wealth Management LLC now owns 234 shares of the medical research company’s stock worth $175,000 after purchasing an additional 95 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Bio-Rad Laboratories by 1.0% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 24,108 shares of the medical research company’s stock worth $17,983,000 after purchasing an additional 250 shares in the last quarter. Toronto Dominion Bank boosted its stake in Bio-Rad Laboratories by 75.4% in the 3rd quarter. Toronto Dominion Bank now owns 59,397 shares of the medical research company’s stock worth $44,307,000 after purchasing an additional 25,538 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Bio-Rad Laboratories by 223.9% in the 3rd quarter. Mackenzie Financial Corp now owns 5,186 shares of the medical research company’s stock worth $3,868,000 after purchasing an additional 3,585 shares in the last quarter. Finally, Trustcore Financial Services LLC lifted its stake in Bio-Rad Laboratories by 812.5% during the 3rd quarter. Trustcore Financial Services LLC now owns 73 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 65 shares during the period. Institutional investors own 63.89% of the company’s stock.

Separately, Zacks Investment Research cut shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating and set a $791.00 price objective for the company. in a research note on Wednesday, September 29th.

Shares of NYSE BIO opened at $628.23 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $545.00 and a 12 month high of $832.70. The company has a 50 day simple moving average of $734.38 and a two-hundred day simple moving average of $742.03. The stock has a market cap of $18.80 billion, a price-to-earnings ratio of 2.85 and a beta of 0.86.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, October 28th. The medical research company reported $3.71 earnings per share for the quarter, beating the consensus estimate of $2.30 by $1.41. The firm had revenue of $747.00 million during the quarter, compared to analyst estimates of $670.36 million. Bio-Rad Laboratories had a net margin of 223.47% and a return on equity of 4.19%. The business’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.00 EPS. Sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 15.33 earnings per share for the current fiscal year.

In other news, EVP Annette Tumolo sold 1,546 shares of Bio-Rad Laboratories stock in a transaction that occurred on Thursday, November 11th. The shares were sold at an average price of $749.00, for a total transaction of $1,157,954.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 27.67% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.

See Also: Discover Your Risk Tolerance

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.